期刊名称：Proceedings of the National Academy of Sciences
印刷版ISSN：0027-8424
电子版ISSN：1091-6490
出版年度：2019
卷号：116
期号：40
页码：19793-19794
DOI：10.1073/pnas.1912315116
出版社：The National Academy of Sciences of the United States of America
摘要：This Reply refers to the Letter by Ruprecht and Mayer titled “On the origin of a pathogenic HERV-W envelope protein present in multiple sclerosis lesions” (1). In their Letter, the authors confirm the specificity of the monoclonal antibody GN-MAb_03 (3B2H4) that we used to detect the pHERV-W ENV protein in multiple sclerosis (MS) lesions (2). We found that pHERV-W ENV is present in lesion-associated myeloid cells and may contribute to neurodegeneration in MS by driving microglia to attack myelinated axons. Our data provide a biomedical rationale for the results of a clinical phase IIb study (ClinicalTrials.gov identifier NCT02782858) in which an anti-pHERV-W ENV monoclonal antibody termed temelimab was found … [↵][1]1To whom correspondence may be addressed.
